Skip to main content

Advertisement

SpringerLink
Log in

Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Extranodal natural killer/T cell lymphoma, nasal type (ENKL) is a highly aggressive tumor with relatively poor prognosis. In this prospective study, we investigated the efficacy and toxicity of a novel GDP-ML regimen (combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase) as front-line treatment in newly diagnosed ENKL. Eligible newly diagnosed stage I/II ENKL patients received sandwich chemoradiation therapy. Patients with stage III/IV disease received an initial 4 cycles of GDP-ML regimen. After 4 cycles, responding patients continued to receive either autologous transplantation or additional two courses of GDP-ML. A total of 44 patients were enrolled with a median follow-up of 26 months. The overall response rate (ORR) were 78.6% for the whole cohort, 84.6% for stage I/II, and 66.7% for stage III/IV, and corresponding complete remission (CR) rates were 61.9%, 76.9%, and 33.3%. The 1- year and 2- year progression-free survival (PFS) rates were 69.3% and 62.9%, and 1- year and 2-year overall survival (OS) rates were 76.5% and 67.4%, respectively. Patients with stage I/II disease showed better 2-year OS rate compared with stage III/IV patients (88.1% vs. 33.2%, p < 0.001). Patients who achieved CR had significantly better 2-year OS rate compared with non-CR patients (90.8% vs. 24.5%, p < 0.001). The main adverse event was hematologic toxicity. Grade 3/4 neutropenia occurred in 59.1% of patients. These results indicate that GDP-ML is an effective and well-tolerated induction regimen with newly diagnosed ENKL patients. This clinical trial was registered on www.chictr.org.cn (ChiCTR-ONC-12002055).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chan JKC, Quintanilla-Martinez L, Ferry JA et al (2017) Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH et al (eds) WHO classification of tumours of Haematopoietic and lymphoid tissues. IARC, Lyon

    Google Scholar 

  2. Li YX, Liu QF, Fang H, Qi SN, Wang H, Wang WH, Song YW, Lu J, Jin J, Wang SL, Liu YP, Lu N, Liu XF, Yu ZH (2009) Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 15(8):2905–2912

    Article  Google Scholar 

  3. Yang QP, Zhang WY, Yu JB (2011) Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol 6(1):77–77

    Article  Google Scholar 

  4. Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C, Zheng J, Liu W, Li G, Chen J (2012) Distribution of lymphoid neoplasms in China: analysis of 4638 cases according to the World Health Organization classification. Am J Clin Pathol 138(3):429–434

    Article  Google Scholar 

  5. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K (2009) Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol 27(33):5594–5600

    Article  CAS  Google Scholar 

  6. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS (2009) Phase II trial of concurrent radiation and weekly Cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 27(35):6027–6032

    Article  CAS  Google Scholar 

  7. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K, NK-cell Tumor Study Group (2010) Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21(5):1032–1040

    Article  CAS  Google Scholar 

  8. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76(11):2351–2356

    Article  CAS  Google Scholar 

  9. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K (1999) P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin a and its analogue, PSC833. Blood 93(2):599–606

    Article  CAS  Google Scholar 

  10. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol 29(33):4410–4416

    Article  CAS  Google Scholar 

  11. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AYH, Chim CS (2012) SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood 120(15):2973–2980

    Article  CAS  Google Scholar 

  12. Kim SJ, Park S, Kang ES, Choi JY, Lim DH, Ko YH, Kim WS (2015) Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol 94(1):71–78

    Article  CAS  Google Scholar 

  13. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O, for the GELA and GOELAMS Intergroup (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood 117(6):1834–1839

    Article  CAS  Google Scholar 

  14. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ (2013) First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 119(2):348–355

    Article  CAS  Google Scholar 

  15. Wang JH, Liang W, Liu CC et al (2016) Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget 7(20):29092–29101

    Article  Google Scholar 

  16. Wang JJ, Dong M, He XH, Li YX, Wang WH, Liu P, Yang JL, Gui L, Zhang CG, Yang S, Zhou SY, Shi YK (2016) GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. Medicine 95(6):e2787

    Article  CAS  Google Scholar 

  17. Shipp M (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 329(14):987–994

    Article  Google Scholar 

  18. Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS (2016) A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol 17(3):389–400

    Article  CAS  Google Scholar 

  19. Henter JI, Horne AC, Arico M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131

    Article  Google Scholar 

  20. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    Article  Google Scholar 

  21. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD, Imaging Subcommittee of International Harmonization Project in Lymphoma (2007) Imaging Subcommittee of International Harmonization Project in lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 25(5):571–578

    Article  Google Scholar 

  22. Kim BS, Kim TY, Kim CW et al (2002) Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy-result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 42(7):779–783

    Article  Google Scholar 

  23. Qi S, Yahalom J, Hsu M, Chelius M, Lunning M, Moskowitz A, Horwitz S (2016) Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leuk Lymphoma 57(11):2575–2583

    Article  CAS  Google Scholar 

  24. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologis 21(12):1471–1482

    Article  CAS  Google Scholar 

  25. Kharfan-Dabaja MA, Kumar A, Ayala E et al (2017) Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T-cell and NK/T-cell lymphomas: an international collaborative effort on behalf of the guidelines Committee of the American Society for blood and marrow transplantation. Biol Blood Marrow Transplant 23(11):1826–1838

    Article  Google Scholar 

  26. Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H (2017) Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother 66(7):877–890

    Article  CAS  Google Scholar 

  27. Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E (2017) PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood 129:2437–2442

    Article  CAS  Google Scholar 

  28. Hari P, Raj RV, Olteanu H (2016) Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma. N Engl J Med 375(15):1501–1502

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China

    Chong Wei, Xinxin Cao, Wei Zhang, Yan Zhang, Wei Wang, Lu Zhang, Chen Yang, Jun Feng, Huacong Cai, Miao Chen, Yueying Mao & Daobin Zhou

Authors
  1. Chong Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinxin Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chen Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Huacong Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Miao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yueying Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Daobin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daobin Zhou.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was done in accordance with the Declaration of Helsinki. The protocol was approved by our institutional review board (ZS-2185).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, C., Cao, X., Zhang, W. et al. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study. Ann Hematol 99, 2801–2809 (2020). https://doi.org/10.1007/s00277-020-04036-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04036-z

Keywords

Search

Navigation